| Literature DB >> 27920431 |
Jacobus F A Jansen1,2, Frank C G van Bussel3,4, Harm J van de Haar3,4,5, Matthias J P van Osch6, Paul A M Hofman3, Martin P J van Boxtel4,5, Robert J van Oostenbrugge4,7,8, Miranda T Schram7, Coen D A Stehouwer7,9, Joachim E Wildberger3,7, Walter H Backes3,4.
Abstract
We investigated whether type 2 diabetes (T2DM) and the presence of cognitive impairment are associated with altered cerebral blood flow (CBF). Forty-one participants with and thirty-nine without T2DM underwent 3-Tesla MRI, including a quantitative technique measuring (macrovascular) blood flow in the internal carotid artery and an arterial spin labeling technique measuring (microvascular) perfusion in the grey matter (GM). Three analysis methods were used to quantify the CBF: a region of interest analysis, a voxel-based statistical parametric mapping technique, and a 'distributed deviating voxels' method. Participants with T2DM exhibited significantly more tissue with low CBF values in the cerebral cortex and the subcortical GM (3.8-fold increase). The latter was the only region where the hypoperfusion remained after correcting for atrophy, indicating that the effect of T2DM on CBF, independent of atrophy, is small. Subcortical CBF was associated with depression. No associations were observed for CBF in other regions with diabetes status, for carotid blood flow with diabetes status, or for CBF or flow in relation with cognitive function. To conclude, a novel method that tallies total 'distributed deviating voxels' demonstrates T2DM-associated hypoperfusion in the subcortical GM, not associated with cognitive performance. Whether a vascular mechanism underlies cognitive decrements remains inconclusive.Entities:
Mesh:
Year: 2016 PMID: 27920431 PMCID: PMC8276879 DOI: 10.1038/s41598-016-0003-6
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Characteristics of the two cognition groupsa.
| Lower cognition (n = 40) | Higher cognition (n = 40) | p-value | |
|---|---|---|---|
| T2DM (%, n) | 55.0 (n = 22) | 47.5 (n = 19) | 0.5b |
| Age (y) | 61.1 ± 9.5 | 62.6 ± 6.6 | 0.4 |
| Sex (male, %, n) | 57.5 (n = 23) | 55.0 (n = 22) | 0.8b |
| Education | 0.8b | ||
| Low (%, n) | 15.0 (n = 6) | 20.0 (n = 8) | |
| Middle (%, n) | 47.5 (n = 19) | 45.0 (n = 18) | |
| High (%, n) | 37.5 (n = 15) | 35.0 (n = 14) | |
| 15-WLT total score | 37.1 ± 10.0 | 49.8 ± 9.2 | <0.001 |
| Executive functioning (sec) | 63.3 ± 35.2 | 34.8 ± 12.7 | <0.001 |
| Verbal fluency | 20.3 ± 4.9 | 27.3 ± 5.5 | <0.001 |
| Cumulative cognition score | −2.30 ± 2.18 | 2.08 ± 1.28 | <0.001 |
Data are mean ± standard deviation. T2DM, type 2 diabetes mellitus; WLT, (verbal memory) Word Learning Test.
aonly participants who were included in the final analysis; Independent samples t-test;
bPearson χ 2 test.
Clinical characteristics of participants with and without T2DM.
| Participants with T2DM (n = 41) | Participants without T2DM (n = 39) | p-value | |
|---|---|---|---|
|
| |||
| Duration of diabetes (years) | 9.8 ± 6.7 | — | |
| Fasting Blood Glucose (mmol/l) | 7.5 ± 1.2 | 5.1 ± 0.3 | <0.001 |
| HbA1c (%) | 6.7 ± 0.4 | 5.6 ± 0.4 | <0.001 |
| HbA1c (mmol/mol) | 50.2 ± 4.9 | 38.0 ± 4.5 | <0.001 |
|
| |||
| None (%) | 12.2 | 100 | <0.001a |
| Insulin (%) | 2.4 | — | |
| Oral medication (%) | 75.6 | — | |
| Insulin and oral medication (%) | 9.8 | — | |
|
| |||
| BMI (kg/m2) | 29.2 ± 3.5 | 24.7 ± 2.8 | <0.001 |
| SBP (mmHg) | 152 ± 18 | 131 ± 18 | <0.001 |
| DBP (mmHg) | 83 ± 10 | 76 ± 13 | 0.013 |
| Cardiovascular disease (%) | 20.5 | 13.5 | 0.4 |
| Hypertension (%) | 95.1 | 38.5 | <0.001a |
| Smoking status, never/former/current (%) | 23.7/71.1/5.3 | 23.7/55.3/21.1 | 0.114a |
|
| |||
| Cumulative cognition score | −0.60 ± 3.17 | 0.40 ± 2.36 | 0.117 |
| Baseline MMSE total score | 28.6 ± 1.4 | 29.4 ± 0.8 | 0.006 |
Data are mean ± standard deviation. T2DM, type 2 diabetes mellitus; HbA1c, glycated hemoglobin; BMI, body mass index, SBP, systolic blood pressure; DBP, diastolic blood pressure; MMSE, Mini-Mental State Examination. Independent samples t-test;
aPearson χ test.
Fraction of negative ‘deviating voxels’ with low flow (hypoperfusion) in GM, relative to intracranial volume.
| Participants with T2DM (n = 41) | Participants without T2DM (n = 39) | p-valuea | |
|---|---|---|---|
| Cerebral cortex | 0.10 ± 0.08% | 0.05 ± 0.03% | <0.001b |
| Frontal cortex | 0.04 ± 0.03% | 0.02 ± 0.01% | 0.003 |
| Temporal cortex | 0.03 ± 0.02% | 0.01 ± 0.01% | <0.001 |
| Occipital cortex | 0.00 ± 0.00% | 0.00 ± 0.00% | 0.249 |
| Parietal cortex | 0.01 ± 0.01% | 0.00 ± 0.00% | <0.001 |
| Subcortical GM | 0.02 ± 0.02% | 0.01 ± 0.01% | <0.001b |
Data are mean ± standard deviation. GM, grey matter; T2DM, type 2 diabetes mellitus.
aIndependent samples t-test,
bSignificant after correcting for age, sex, and atrophy.
Figure 1Normalized T1 weighted images, with as overlay the percentage of participants within a group displaying negatively ‘deviating voxels’ (using threshold Z < −2.576, indicative of hypoperfusion) for participants without T2DM (upper figure) and participants with T2DM (lower figure). Note the high percentage (indicating hypoperfusion) for T2DM in the subcortical GM, especially in the nucleus accumbens and caudate structures.
Figure 2(A) Coronal maximum intensity projections derived from phase-contrast angiography with indication of the slice for quantitative flow measurement in the internal carotid artery in a participant with T2DM. (B) Sagittal T1 weighted image with labeling slice (red), which was positioned at the same location of the slice for quantitative flow estimation, and imaging volume (green). (C) Resulting transverse CBF map. (D) Magnitude and (E) phase images of the carotid region, 1 left internal carotid artery, 2 left vertebral artery, 3 right internal carotid artery, 4 right vertebral artery.